Clinical Trials Logo

High-risk MDS clinical trials

View clinical trials related to High-risk MDS.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02159040 Completed - High Risk MDS Clinical Trials

Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.

Start date: September 2014
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to compare the overall response rate (inclusive of complete response, partial response and hematologic improvement) per IWG 2006 criteria in patients with higher risk MDS treated with azacitidine with or without deferasirox achieved over the course of one year. Hematologic improvement must be maintained for at least 8 weeks.